Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR.From December 2003 to August 2005, 572 pat ...

Cetuximab, a chimeric mouse–human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck ...

We previously showed that the combination of weekly carboplatin, paclitaxel and cetuximab was associated with reduced risk of grade 3/4 toxicities, which makes it an ideal regimen in this setting.

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes ...

Cetuximab is approved for use in head and neck cancer, but only for specific indications (i.e., as a single agent in patients with platinum-resistant disease) or in combination with radiation in ...

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Monoclonal antibodies like cetuximab bind to proteins on the surface of cancer cells, halting their growth and proliferation. In contrast, durvalumab, an immune checkpoint inhibitor, ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...

Cetuximab (Erbitux) plus chemotherapy showed higher progression-free survival (PFS) and overall survival (OS) for patients with metastatic colorectal cancer (mCRC), according to one study.

Cetuximab is a monoclonal antibody used in the treatment of cancer. The agent targets and binds to epidermal growth factor receptors, inhibiting it its ability to send signals to cancer cells that ...

Xuan T, Wang Z, Meng S, Li J, Li J, Cao F, Qu L. Efficacy and safety of maintenance therapy using cetuximab in patients with metastatic colorectal cancer: retrospective study. Cancer Manag Res ...

Cetuximab links up with proteins on the surface of cancer cells, curbing their growth. But durvalumab blocks a separate protein on the cell's surface, ...